US OptionsDetailed Quotes

CVM240920C1500

Watchlist

0.05
0.000.00%

15min DelayClose Aug 30 16:00 ET

0.00High0.00Low

CEL-SCI Stock Discussion

Stock Region

Jul 29 09:28

Healthcare Company Demonstrates Promising Clinical Results For Cancer Treatment

CEL-SCI's Phase 3 Population Analysis for Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well-Balanced Patient Population and Confidence in Clinical Results.
Head and neck cancers (HNC) remain a global health challenge, impacting thousands of individuals each year. Advances in immunotherapy have offered new hope for improving patient outcomes, particularly concerning survival rates. In this context...